The significant EPS miss suggests potential operational challenges or higher-than-expected expenses. Monitor the conference call for guidance updates and any commentary on pipeline progress or cost containment.
Price Chart
Executive Summary
Phathom Pharmaceuticals reported Q1 2026 EPS of -$0.37, missing consensus of -$0.10 by 289.5%, a significant earnings miss. Revenue came in at $73.0M, though no consensus estimate was provided for comparison. The miss raises concerns about operational performance and expense management, likely pressuring the stock near-term.
Key Financial Metrics
Key Facts
- Q1 2026 EPS of -$0.37 missed consensus of -$0.10 by 289.5%
- Revenue of $73.0M reported; no consensus estimate available
- Management to host conference call on July 30, 2026 at 8:00 am EDT
Financial Impact
EPS miss of -$0.27 per share vs consensus; revenue $73.0M
Risk Factors
- Further downside if guidance is lowered or cash burn accelerates
- Potential for negative analyst revisions following the miss
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3329653 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Jul 30, 2026 9w ago | 8-K | $9.03 $8.94 | ▼ −1.00% | ▼ −4.96% | $6.92 (−23.37%) |
Jul 30, 2026 9w ago | Press Release | $9.03 $8.94 | ▲ +1.00% | ▲ +4.96% | $6.92 (+23.37%) |
Jul 20, 2026 10w ago | Press Release | $10.65 $9.28 | ▲ +12.86% | ▲ +16.98% | $6.92 (+35.02%) |
May 20, 2026 19w ago | Press Release | $11.87 $10.88 | ▼ −8.34% | ▼ −9.08% | $6.92 (−41.70%) |
May 1, 2026 22w ago | Press Release | $12.01 $9.24 | ▼ −23.06% | ▼ −28.35% | $6.92 (−42.38%) |
Apr 30, 2026 22w ago | Press Release | $11.20 $10.32 | ▼ −7.86% | ▼ −12.82% | $6.92 (−38.21%) |
Apr 7, 2026 25w ago | DEFA14A | $11.55 $12.87 | ▲ +11.43% | ▲ +1.65% | $6.92 (−40.09%) |
Feb 26, 2026 31w ago | 8-K | $13.56 $10.79 | ▼ −20.43% | ▼ −14.03% | $6.92 (−48.97%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access